Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus POLYCILLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus POLYCILLIN N.
PENICILLIN-2 vs POLYCILLIN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, and activating autolytic enzymes. It is bactericidal against susceptible organisms.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
1-2 g IV/IM every 4-6 hours
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Terminal elimination half-life: 0.5-1 hour (normal renal function); increases to 7-10 hours in anuria. Prolonged in neonates (2-4 hours).
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Renal: 60-80% unchanged via glomerular filtration and tubular secretion. Biliary: ~20% excreted in bile and feces. Small amount metabolized to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic